NANOG signaling promotes metastatic capability of immunoedited tumor cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyo-Jung | - |
dc.contributor.author | Noh, Kyung Hee | - |
dc.contributor.author | Lee, Young-Ho | - |
dc.contributor.author | Song, Kwon-Ho | - |
dc.contributor.author | Oh, Se Jin | - |
dc.contributor.author | Kim, So Youn | - |
dc.contributor.author | Kim, Tae Woo | - |
dc.date.accessioned | 2021-09-04T15:48:44Z | - |
dc.date.available | 2021-09-04T15:48:44Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 0262-0898 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93448 | - |
dc.description.abstract | Metastatic recurrence after cancer treatments with radiation, cancer drugs, or even immunotherapeutic agents (cytokine, antibody, lymphocyte etc.) is often intractable and fatal for cancer patients. Therefore, molecular understanding of metastatic recurrence is necessary. Recently, these recurrent and metastatic tumor cells with resistance to cancer drugs have been reported to possess stem-like attributes and epithelial-mesenchymal transition (EMT) phenotype. Previously, we also found that antigen-specific cytotoxic T lymphocyte (CTL)-mediated immunotherapy conferred tumor cells with immune-resistant and stem-like phenotypes by hyper-activating NANOG/TCL1/AKT signaling axis. In this study, we report that these immunoedited cells have high metastatic capability and phenotypes. These cells exhibit enhanced migration, infiltration, and invasiveness in vitro as well as formation of metastatic lung nodules in vivo. Moreover, they display EMT-like features characterized by increased expression of BMI1 and TWIST1. Importantly, these pleiotropic phenotypes of metastasis through the expression of the EMT-associated molecules were critically dependent on the NANOG/TCL1A/AKT signaling axis, which was also conserved across multiple types of human cancer. Thus, we provide proof of the principle that inhibition of the NANOG axis is an effective strategy to control metastasis of immunoedited cancer, particularly, after CTL-based immunotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject | CANCER STEM-CELLS | - |
dc.subject | TRANSCRIPTION FACTORS | - |
dc.subject | POOR-PROGNOSIS | - |
dc.subject | MEDIATED LYSIS | - |
dc.subject | IFN-GAMMA | - |
dc.subject | BMI1 | - |
dc.subject | RESISTANCE | - |
dc.subject | CARCINOMA | - |
dc.subject | PROGRESSION | - |
dc.title | NANOG signaling promotes metastatic capability of immunoedited tumor cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Kwon-Ho | - |
dc.contributor.affiliatedAuthor | Kim, Tae Woo | - |
dc.identifier.doi | 10.1007/s10585-015-9717-2 | - |
dc.identifier.scopusid | 2-s2.0-84930572335 | - |
dc.identifier.wosid | 000355926700003 | - |
dc.identifier.bibliographicCitation | CLINICAL & EXPERIMENTAL METASTASIS, v.32, no.5, pp.429 - 439 | - |
dc.relation.isPartOf | CLINICAL & EXPERIMENTAL METASTASIS | - |
dc.citation.title | CLINICAL & EXPERIMENTAL METASTASIS | - |
dc.citation.volume | 32 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 429 | - |
dc.citation.endPage | 439 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | EPITHELIAL-MESENCHYMAL TRANSITION | - |
dc.subject.keywordPlus | CANCER STEM-CELLS | - |
dc.subject.keywordPlus | TRANSCRIPTION FACTORS | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | MEDIATED LYSIS | - |
dc.subject.keywordPlus | IFN-GAMMA | - |
dc.subject.keywordPlus | BMI1 | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordAuthor | NANOG | - |
dc.subject.keywordAuthor | Metastasis | - |
dc.subject.keywordAuthor | EMT | - |
dc.subject.keywordAuthor | Immunoedited cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.